

JunHe LLP has profound expertise, and they (JunHe) have notable skills acting for clients from the education and healthcare sectors.

—Chambers Greater China Region

## Life Science and Health

At JunHe, we have been counseling domestic and foreign life sciences companies on their investments in the life sciences and healthcare sector in China since the 1990s. After thirty years of practice, JunHe has become one of the few full-service law firms in China with particularly strong practice in this sector. We have strong expertise in the entire life cycle of medical products and services. We render quality services to all stakeholders in the industry. Our strong expertise and extensive experience in the sector have been repeatedly illustrated by the pioneering deals we help our clients to achieve.

### Our Team

Our life sciences and healthcare practice group comprises professionals from multidisciplinary practices, including dozens of partners and approximately 100 associates. Our life sciences and healthcare team of lawyers has vast experience in advising clients in the areas of mergers and acquisitions, capital markets, private equity/venture capital, intellectual property, compliance and dispute resolution. They have been involved in many high profile transactions and have represented the most active clients in the life sciences and healthcare sectors, offering them value-added, creative and practical legal solutions.

### We offer our clients legal capabilities and services across the whole industry chain of pharmaceutical products, including:

- Drug discovery and patent application;
- Drug-diagnostic co-development;
- Preclinical research services;
- Design, management, filing and technical cooperation of clinical trial plans;
- IP licensing and transfer in every stage of drug development;
- Registration of drug license holders, applications for new drug approvals, and registration of imported drugs;
- Commercialization, manufacturing, marketing, sale and distribution of drugs;
- Lifecycle pharmaceutical compliance consulting;
- Drug adverse events and recalls, civil claims by patents and clinical trial participants; and Government investigations, administrative penalties and dispute resolutions with respect to the foregoing issues.

### We advise life sciences and healthcare companies on the full spectrum of issues in every stage of the life cycle, including:

- Incubation and acceleration of new enterprises and products;
- Establishment of, and license application for, various life sciences and healthcare companies;
- Angel investment and seed funding;

JunHe, founded in Beijing in 1989, is one of the first private partnership law firms in China. Since its establishment, JunHe has grown to be one of the largest and most recognized Chinese law firms. The firm has twelve offices around the world and a team comprised of more than 1070 professionals, including over 320 partners and legal counsel, as well as over 750 associates and legal translators.



**(JunHe) Acts for clients in a variety of industries, and is increasingly active in the pharmaceutical and health-care sectors.**

—Chambers Asia-Pacific 2021

Corporate restructuring, including the restructuring of red-chip structures and the restructuring of dismantled red-chip structures;

- Design and implementation of employee incentive plans;
- Corporate mergers and acquisitions, joint ventures and collaborations;
- Early-stage venture capital investments and subsequent pre-IPO private equity financing;
- Domestic and overseas IPOs on China's A-share market, the HKEx main board, NYSE and Nasdaq;
- Post-IPO asset restructuring, acquisition, going private and delisting of listed companies, and relisting of delisted companies on the STAE market;
- PIPE, SPAC, back door listings and spin-offs;
- Debt restructuring of public or private companies;
- Corporate dissolution, liquidation and bankruptcy;
- Various dispute resolutions in connection with the foregoing matters; and
- Providing general legal counseling services for the day-to-day operation of life sciences and healthcare companies.

**We represent all types of businesses in the life sciences and healthcare industry, such as:**

- Multinational and major domestic life sciences and medical device companies;
- Biotechs, biopharmas and big pharmas;
- Medical equipment production, API and intermediate production companies;
- Contract manufacturing organizations (CMO);
- Contract research organizations (CRO);
- Contract development and manufacturing organizations (CDMO);
- Contract sales organizations (CSO);
- Service providers of pharmaceutical inspections;
- Various healthcare facilities, such as full-service hospitals, specialty hospitals, chain medical examination institutions and medical clinics; and
- Domestic and foreign investors and financial advisors focusing on investments in the life sciences and healthcare sector.

**We provide a full range of legal services to meet the needs of our clients across all aspects of life sciences and healthcare issues:**

- Legal counseling on general corporate matters;
- Legal advice on transactions and the design of transaction structures;
- Legal due diligence;
- Drafting and negotiation of transaction documents;
- Assisting in closing;
- Post-closing integration;
- Dispute resolution;
- Issuing legal opinion;
- Design and implementation of employee incentive plans;
- Issuing legal opinion on IPO projects;
- Providing legal advice and assistance in government investigations;
- Consulting, internal investigations and assistance with respect to corporate compliance in matters including but not limited to pharmacovigilance compliance, anti-commercial bribery, data security and privacy protection, EHS audits, antitrust, and human genetic resources compliance; and
- Merger control notifications and legal advice on other antitrust matters.

Healthcare Law Firm of the Year  
2021

ALB China Law Awards

Deals of the Year - Harbin Pharma's  
\$300M Investment in GNC

2018

PRC Firm of the Year - Healthcare &  
Life Sciences

2017

China Law & Practice Awards

Deals of the Year - Grifols Invested in  
Shanghai RAAS through share Swap

2020

Deals of the Year - RemeGen's Hong  
Kong Listing

2020

Deals of the Year - JD Health's US\$1  
billion series A Financing

2019

Deals of the Year - Bayer's  
Acquisition of all Shares of Dihon  
Pharmaceutical Group

2015

Deals of the Year - Anti-Dumping  
Investigation by MOFCOM of  
Haemodialysis Control Unit  
Originated from EU and Japan

2015

China Business Law Deals of the Year

Merger Control Filing for Acquisition  
of Pfizer's Consumer Healthcare  
Business by GlaxoSmithKline

2020

Global Competition Review, Merger Control  
Matter of the Year for Asia-Pacific/Middle  
East/Africa